Drugs / BI 695502
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT01608087 | May → Nov 2012 | — | Boehringer Ingelheim | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT02776683 | Jun 2016 → Oct 2018 | colorectal neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02272413 | Jul 2015 → Jun 2017 | non-small cell lung carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-11-16 | Boehringer Ingelheim | Results Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin® prnewswire.com ↗
Boehringer Ingelheim today announced new data from the Phase I INVICTAN®-1 study, which show that BI 695502, its bevacizumab biosimilar candidate, is bioequivalent to U.S.-licensed and EU-approved Avastin®. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-11-16 | Boehringer Ingelheim | Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin® prnewswire.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 695502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02272413 ↗ |
| Route | Intravenous | “a single intravenous infusion of 1 mg/kg of BI 695502” PMID 28651442 ↗ Jul 2017 |